VaccinesNews.net

Vaccines Xagena

Search results for "Human papillomavirus"

Gardasil ( quadrivalent human papillomavirus types 6, 11, 16, 18, recombinant vaccine ), an investigational vaccine, prevented 100 percent of high-grade cervical pre-cancers and non-invasive cervical ...


The FDA ( U.S. Food and Drug Administration ) has approved Gardasil, the first vaccine developed to prevent cervical cancer, precancerous genital lesions and genital warts due to human papillomavirus ...


The FDA ( Food and Drug Administration ) has approved Gardasil, the first vaccine developed to prevent cervical cancer, precancerous genital lesions and genital warts due to human papillomavirus ( HPV ...


On June 8th 2006, the FDA ( Food and Drug Administration ) announced the approval of Gardasil, and on June 29th the Advisory Committee on Immunizations Practices ( ACIP ) voted to recommend adding Gar ...


In a commentary published in the Canadian Medical Association Journal ( CMAJ ), Abby Lippman, an epidemiologist at McGill University in Montreal, Canada, and colleagues wrote that there is no urgent n ...


HPV infection is necessary for the development of cervical cancer and the vaccine may prevent primary infection with HPV types 16 and 18. However, Abby Lippman, chair of the Canadian Women's Health N ...


The EMEA ( European Medicines Agency ) has received reports of deaths in women who had previously received Gardasil, including two reports concerning the sudden and unexpected deaths of two young wome ...


The FDA ( Food and Drug Administration ) has approved the vaccine Gardasil for the prevention of anal cancer and associated precancerous lesions due to human papillomavirus ( HPV ) types 6, 11, 16, an ...


Initial vaccinations for human papillomavirus ( HPV ) at a young age is important for maximizing quadrivalent HPV vaccine effectiveness according to a Swedish study.HPV vaccination programs have been ...


Merck & Co has announced that in the pivotal phase III efficacy study, its investigational 9-valent HPV vaccine ( V503 ) prevented approximately 97% of cervical, vaginal and vulvar pre-cancers cau ...


Determining vaccine dose-level protection is essential to minimize program costs and increase mass vaccination program feasibility. Currently, a 3-dose vaccination schedule is recommended for both t ...


The objective of a study was to measure the effectiveness of the quadrivalent human papillomavirus ( HPV ) vaccine against cervical abnormalities four years after implementation of a nationally funded ...


Although adolescent girls are the main population for prophylactic human papillomavirus ( HPV ) vaccines, adult women who remain at risk of cervical cancer can also be vaccinated. Data from the inte ...